SCHOTT KAISHA launches customizable prefillable glass syringes in India

Published On 2019-01-01 04:00 GMT   |   Update On 2021-08-16 07:21 GMT

Rishad Dadachanji, Director, SCHOTT KAISHA shares, "The syriQ BioPure syringes, manufactured in St. Gallen, Switzerland, combine features to ensure stability and safe administration of sensitive drugs. Our clients often work with complex biologicals that require an extremely reliable PFS solution. We are happy with the response that this offering is receiving from our existing and potential clients."


Mumbai: Pharmaceutical packaging company, SCHOTT KAISHA has launched a highly specialized glass syringe portfolio in India, that further minimizes the risk of drug/container interactions for sensitive drugs. As part of its German partner SCHOTT's iQ platform, syriQ BioPure is a hugely customizable glass prefillable Staked-needle syringe (PFS) specifically designed to keep sensitive drugs stable over shelf life and shorten time to market while making administration more convenient for patients.


Complex biotech drugs always face a threat of interacting with their container system. These interactions cannot be predicted and can lead to unintentional aggregation or deterioration of the drug which may eventually compromise the total cost of ownership, the shelf life of the drug and treatment efficiency.


Rishad Dadachanji, Director, SCHOTT KAISHA shares, "The syriQ BioPure syringes, manufactured in St. Gallen, Switzerland, combine features to ensure stability and safe administration of sensitive drugs. Our clients often work with complex biologicals that require an extremely reliable PFS solution. We are happy with the response that this offering is receiving from our existing and potential clients."


A Quality by Design approach, benchmark manufacturing and quality control processes using breakthrough inspection technology, combined with best-in-class components has established syriQ BioPure as a preferred container solution globally. Its application has proven to be beneficial in achieving:




  • Ultra-low tungsten residuals (ICP-MS certificate available)

  • Uniform silicon layer

  • Low adhesive residuals

  • Low E&L from latest high-quality elastomer formulations


The new glass syringes work with leading safety and autoinjector devices, meeting market demand for products that can be administered at home for patient comfort. Seamless integration into these devices is reached thanks to the syringe's high dimensional accuracy.


Also Read: Minister notifies Parliament: Precautions to curb unsafe medical syringes in the market
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News